About The Study: Compared with prior decades, the number of new dermatologic drug approvals by the Food and Drug Administration (FDA) increased between 2012 and 2022. Nearly half of these drugs were considered first in class or first in indication, and several were deemed clinically useful or to have high added therapeutic benefit by health technology assessment organizations in Germany, Canada, or France.
Authors: Ravi Gupta, M.D., M.S.H.P., of the Johns Hopkins University School of Medicine in Baltimore, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamadermatol.2023.5036)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2023.5036?guestAccessKey=c6e3efa5-5965-40d7-b5e1-3492f765a9f6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122023
JAMA Dermatology